Objective responses to avelumab after ≥36 months of follow-up
| Response | N=88 |
| Confirmed best overall response, n (%) | |
| Complete response | 10 (11.4) |
| Partial response | 19 (21.6) |
| Stable disease | 9 (10.2) |
| Progressive disease | 32 (36.4) |
| Not evaluable | 18 (20.5) |
| Objective response rate (95% CI), % | 33.0 (23.3 to 43.8) |
| Disease control rate, % | 43.2 |
| Response durability | n=29 |
| Median duration of response (95% CI), months | 40.5 (18.0 to not estimable) |
| Range | 2.8–41.5 |
| Proportion with duration of response (95% CI), % | |
| ≥6 months | 93 (75 to 98) |
| ≥1 year | 71 (51 to 85) |
| ≥2 years | 67 (47 to 82) |
| ≥3 years | 52 (26 to 73) |